Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Queensland Health
Colorcon
Covington
Federal Trade Commission
Johnson and Johnson
UBS
Moodys
Citi

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,583,233

« Back to Dashboard

Title: Retroviral protease inhibiting compounds
Abstract:A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Inventor(s): Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing L. (Gurnee, IL), Zhao; Chen (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Filing Date:Mar 30, 1995
Application Number:08/413,290
Claims:1. A compound of the formula: ##STR18## wherein R.sub.1 is monosubstituted thiazolyl or monosubstituted oxazolyl wherein the substituent is selected from (i) heterocyclic wherein the heterocyclic is selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyl and wherein the heterocyclic is unsubstituted or substituted with a substituent selected from halo, C.sub.1 -to-C.sub.6 -loweralkyl, hydroxy, C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S-- and (ii) (heterocyclic)-C.sub.1 -to-C.sub.6 -alkyl wherein heterocyclic is defined as above;

n is 1, 2or3;

R.sub.2 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl;

R.sub.3 is C.sub.1 -to-C.sub.6 -loweralkyl;

R.sub.4 and R.sub.4a are independently selected from phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from (i) halo, (ii) C.sub.1 -to-C.sub.6 -loweralkyl, (iii) hydroxy, (iv) C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and (v) C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S--;

R.sub.6 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl;

R.sub.7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted or substituted with C.sub.1 -to-C.sub.6 -loweralkyl;

X is hydrogen and Y is --OH; and

Z is absent, --O--, --S--, --CH.sub.2 -- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 -to-C.sub.6 -loweralkyl, C.sub.3 -to-C.sub.7 -cycloalkyl, --OH or --NHR.sub.8a wherein R.sub.8a is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein n is 1;R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is thiazolyl or oxazolyl.

3. The compound of claim 1 wherein R.sub.1 is 2-monosubstituted-4-thiazolyl or 2-monosubstituted-4-oxazolyl wherein the substituent is selected from (I) heterocyclic wherein the heterocyclic is selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyl and wherein the heterocyclic is unsubstituted or substituted with a substituent selected from halo, loweralkyl, hydroxy, alkoxy and thioalkoxy and (II) (heterocyclic)alkyl wherein heterocyclic is defined as above; n is 1;R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is 5-thiazolyl or 5-oxazolyl.

4. The compound of claim 1 wherein n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O-- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 -to-C.sub.6 -loweralkyl.

5. The compound of claim 1 wherein n is 1;R.sub.2 is hydrogen; R.sub.3 is methyl or isopropyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O--.

6. The compound of claim 1 wherein n is 1;R.sub.2 is hydrogen; R.sub.3 is isopropyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; Z is --N(R.sub.8)-- wherein R.sub.8 is methyl; X is hydrogen and Y is --OH.

7. A compound selected from the group consisting of:

(2S,3S5S)-5-(N-(N-((N-Methyl-N-((2-(2-thiazolyl)-4-thiazolyl)methyl)amino)- carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphe nyl-3-hydroxyhexane;

(2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-thiazolyl)methyl-4-thiazolyl)methyl) aminocarbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6- diphenyl-3-hydroxyhexane;

(2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-pyrrolidinyl)methyl-4-thiazolyl)meth yl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)- 1,6-diphenyl-3-hydroxyhexane;

(2S,3S,5S)-5-(N-(N-((2-(4-Morpholinyl)-4-thiazolyl)methoxycarbonyl)valinyl) amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexa ne;

(2S,3S,5S)-2-(N-(N-((2-(4-Morpholinyl)-4-thiazolyl)-methoxycarbonyl)valinyl )amino)-5-(N-((5-methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane;

(2S,3S,5S)-5-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl )amino)-2-(N-((5thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexa ne;

(2S,3S,5S)-2-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)-methoxycarbonyl)valiny l)amino)-5-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhe xane;

(2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-pyrrolidinyl)methyl-4-thiazolyl)meth yl)amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1 ,6-diphenyl-3-hydroxyhexane;

(2S,3S,5S)-5-(N-(N-((2-(4-Morpholinyl)-4-thiazolyl)methoxycarbonyl)valinyl) amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexan e;

(2S,3S,5S)-2-(N-(N-((2-(4-Morpholinyl)-4-thiazolyl)-methoxycarbonyl)valinyl )amino)-5(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexan e;

(2S,3S,5S)-5-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)methoxycarbonyl)valinyl )amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexa ne;

(2S,3S,5S)-2-(N-(N-((2-(1-Pyrrolidinyl)-4-thiazolyl)-methoxycarbonyl)valiny l)amino)-5-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhex ane;

(2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-thiazolyl)-4-thiazolyl)methyl)aminoc arbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane;

(2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(2-thiazolyl)methyl-4-thiazolyl)methyl) amino)carbonyl)valinyl)amino)-2-(N-((5-oxazolyl)methoxycarbonyl)amino)-1,6- diphenyl-3-hydroxyhexane; and

(2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-(1-pyrrolidinyl)-4-thiazolyl)methyl)ami no)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-di phenyl-3-hydroxyhexane;

or a pharmaceutically acceptable salt thereof.

8. A compound of the formula: ##STR19## wherein R.sub.1 is monosubstituted thiazolyl or monosubstituted oxazolyl wherein the substituent is selected from (i) heterocyclic wherein the heterocyclic is selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyl and wherein the heterocyclic is unsubstituted or substituted with a substituent selected from halo, C.sub.1 -to-C.sub.6 -loweralkyl, hydroxy, C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S-- and (ii) (heterocyclic)-C.sub.1 -to-C.sub.6 -alkyl wherein heterocyclic is defined as above;

n is 1,2 or 3;

R.sub.2 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl;

R.sub.4 and R.sub.4a are independently selected from phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from (i) halo, (ii) C.sub.1 -to-C.sub.6 -loweralkyl, (iii) hydroxy, (iv) C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and (v) C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S--;

R.sub.6 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl;

R.sub.7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted and R.sub.3 is C.sub.2 -to-C.sub.6 -loweralkyl and Z is absent, --O--, --S-- or --CH.sub.2 --; or

R.sub.7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is substituted with C.sub.1 -to-C.sub.6 -loweralkyl and R.sub.3 is C.sub.1 -to-C.sub.6 -loweralkyl and Z is absent, --O--, --S--, --CH.sub.2 -- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 -to-C.sub.6 -loweralkyl, C.sub.3 -to-C.sub.7 -cycloalkyl, --OH or --NHR.sub.8a wherein R.sub.8a is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; and

X is --OH and Y is hydrogen;

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 8 wherein n is 1;R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is thiazolyl or oxazolyl.

10. The compound of claim 8 wherein R.sub.1 is 2-monosubstituted-4-thiazolyl or 2-monosubstituted-4-oxazolyl wherein the substituent is selected from (i) heterocyclic wherein the heterocyclic is selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyl and wherein the heterocyclic is unsubstituted or substituted with a substituent selected from halo, loweralkyl, hydroxy, alkoxy and thioalkoxy and (ii) (heterocyclic)alkyl wherein heterocyclic is defined as above; n is 1;R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is 5-thiazolyl or 5-oxazolyl.

11. The compound of claim 8 wherein n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O--.

12. The compound of claim 8 wherein n is 1; R.sub.2 is hydrogen; R.sub.3 is methyl or isopropyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O--.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Federal Trade Commission
Queensland Health
Express Scripts
Accenture
Covington
Colorcon
Cipla
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.